Close Menu

NEW YORK (360Dx) – Chembio Diagnostics said after the close of the market on Wednesday that its total revenues grew 22 percent year over year, as its product revenues jumped 19 percent.

For the three months ended March 31, total revenues reached $7.7 million, up from $6.3 million in Q1 2017. Product revenues rose to $6.4 million from $5.4 million, while license and royalty revenues more than doubled to $201,931 from $100,000, and R&D, milestone, and grant revenues increased 38 percent to $1.1 million from $797,740.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.